+86-28-82633987sales@biopurify.com
cnen
  • iso9001 iso9001
  • iso17025 iso17025
  • usp usp
Alternate Text
Home > Product Catalog > Compound Types > Phenols

Dihydrokawain

CAS No.:587-63-3
Dihydrokawain
Catalogue No.: BP0495
Formula: C14H16O3
Mol Weight: 232.279
Botanical Source: Piper methysticum Forst
Contacts
+86-28-82633860  +86-18080483897
skype skype
Email: sales@biopurify.com biopurify@gmail.com

Dihydrokawain

CAS No.:587-63-3

Dihydrokawain
Catalogue No.: BP0495
Formula: C14H16O3
Mol Weight: 232.279
Contacts
+86-28-82633860  +86-18080483897
skype skype
Email: sales@biopurify.com biopurify@gmail.com
Over 15 years of industry experience in phytochemicals from R&D(reference substances) to Industrialization, please feel free to contact us!

Dihydrokawain SKU Information

Purity:98%Brand:Biopurify
Catalog NoPackage PurityOriginal PricePrice Inventory Quantity Operating
BP1276-20mg20mg98% $36.00 $36.00 In stock
BP1276-100mg100mg98% $120.00 $120.00 In stock

Dihydrokawain Descrtption

Synonym name: Marindinin
Catalogue No.: BP0495
Cas No.: 587-63-3
Formula: C14H16O3
Mol Weight: 232.279
Botanical Source: Root of Piper methysticum and Aniba gigantifolia

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.

For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.

 

 

Description:

Dihydrokavain may play an important role in regulation of GABAergic neurotransmission, it non-competitively inhibits the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. Dihydrokavain may treat sleep disturbances, as well as stress and anxiety.

 

References:

Planta Med. 2002 Dec;68(12):1092-6.    

Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation.

METHODS AND RESULTS:

Using an in vitro neonatal rat gastric-brainstem preparation, the activity of majority neurons recorded in the nucleus tractus solitarius (NTS) of the brainstem were significantly inhibited by GABA A receptor agonist, muscimol (30 microM), and this inhibition was reversed by selective GABA A receptor antagonist, bicuculline (10 microM). Application of kavalactones (300 microg/ml) and Dihydrokavain (300 microM) into the brainstem compartment of the preparation also significantly reduced the discharge rate of these NTS neurons (39 % and 32 %, respectively, compared to the control level), and this reduction was partially reversed by bicuculline (10 microM). Kavalactones or Dihydrokavain induced inhibitory effects were not reduced after co-application of saclofen (10 microM; a selective GABA B receptor antagonist) or naloxone (100 nM; an opioid receptor antagonist). Pretreatment with kavalactones (300 microg/ml) or Dihydrokavain (300 microM) significantly decreased the NTS inhibitory effects induced by muscimol (30 microM), approximately from 51 % to 36 %. 

CONCLUSIONS:

Our results demonstrated modulation of brainstem GABAergic mechanism by kavalactones and Dihydrokavain, and suggested that these compounds may play an important role in regulation of GABAergic neurotransmission.    

 

HPLC of Dihydrokawain

Checkout